Effective Date:

Monday, February 07, 2011

New Tests and Test Updates

Modified Date: 12/17/2010

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, February 07, 2011

New Tests - Tests recently added to the NMS Labs test menu. *New Tests are effective immediately.*

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.

NMS LABS
3701 Welsh Road
Willow Grove, PA 19090
www.NMSLabs.com

New Tests and Test Updates

Test Code	Test Name	New Test	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
0021TI	Acetaldehyde, Tissue							•		
0155B	Actifed®, Blood		•							
0155SP	Actifed®, Serum/Plasma		•							
9305U	Anabolic Steroids Screen, Urine	•								
9530U	Antidepressant Screen, Urine (CSA)									•
9022B	Antidepressants Screen - Expanded, Blood	•								
9022SP	Antidepressants Screen - Expanded, Serum/Plasma	•								
9022U	Antidepressants Screen - Expanded, Urine	•								
5638SP	Antihistamines Confirmation, Serum/Plasma								•	
5638U	Antihistamines Confirmation, Urine								•	
0408B	Antihistamines Panel, Blood								•	
0408SP	Antihistamines Panel, Serum/Plasma								•	
0408U	Antihistamines Panel, Urine								•	
9108SP	Antihistamines Screen, Serum/Plasma								•	
9108U	Antihistamines Screen, Urine								•	
6100LI	Dialysis Water Analysis				•					
5503B	Dimethyltryptamine Confirmation, Blood								•	
5503SP	Dimethyltryptamine Confirmation, Serum/Plasma								•	
5503U	Dimethyltryptamine Confirmation, Urine								•	
9156B	Dimethyltryptamine Screen, Blood								•	
9156SP	Dimethyltryptamine Screen, Serum/Plasma								•	
9156U	Dimethyltryptamine Screen, Urine								•	
1693B	Dimethyltryptamine, Blood								•	
1693SP	Dimethyltryptamine, Serum/Plasma								•	
1693U	Dimethyltryptamine, Urine								•	
1912SP	Embeda®, Serum/Plasma		•							
1912U	Embeda®, Urine		•							
1955U	Esgic®, Urine		•							
2087B	Fiorinal®, Blood		•							

New Tests and Test Updates

Test Code	Test Name	New Test	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
2087SP	Fiorinal®, Serum/Plasma		•							
2087U	Fiorinal®, Urine		•							
2321TI	Hydrocarbon and Oxygenated Volatiles Panel, Tissue							•		
2365FL	Hydroxyzine, Fluid							•		
2365U	Hydroxyzine, Urine							•		
2411TI	Inhalants Panel, Solvents, Tissue							•		
5620FL	Pheniramine Confirmation, Fluid								•	
9231FL	Pheniramine Screen, Fluid								•	
3560B	Pheniramine, Blood								•	
9551B	Sildenafil and Metabolite Screen (Add-On), Blood (CSA)				•					
4197B	Sildenafil and Metabolite, Blood				•					
4127B	Suboxone® - Free, Blood		•							
4127SP	Suboxone® - Free, Serum/Plasma		•							
4127U	Suboxone® - Total, Urine		•							
3230B	Symbyax®, Blood		•							
3230FL	Symbyax®, Fluid		•							
3230SP	Symbyax®, Serum/Plasma		•							
3230TI	Symbyax®, Tissue		•							
3230U	Symbyax®, Urine		•							
4280U	Synthetic Cannabinoid Metabolites (Qualitative), Urine	•								
9561U	Synthetic Cannabinoid Metabolites Screen (Qualitative), Urine (Forensic)	•								
9561B	Synthetic Cannabinoids Screen (Qualitative), Blood (Forensic)	•								
9560B	Synthetic Cannabinoids Screen, Blood (Forensic)	•								
4541SP	Triavil®, Serum/Plasma		•							

New Tests and Test Updates

New Tests

9305U Anabolic Steroids Screen, Urine **Effective Immediately**

Scope of Analysis:	Androstenedione [LC-MS/MS], Bolasterone [LC-MS/MS], Boldenone [LC-MS/MS], Clenbuterol [LC-MS/MS], Clostebol Metabolite [LC-MS/MS], Clostebol [LC-MS/MS], Creatinine [Colorimetry], Drostanolone Metabolite [LC-MS/MS], Epitestosterone [LC-MS/MS], Fluoxymesterone [LC-MS/MS], Methandienone Metabolite [LC-MS/MS], Methandienone [LC-MS/MS], Methenolone [LC-MS/MS], Methyltestosterone [LC-MS/MS], Nandrolone Metabolite [LC-MS/MS], Nandrolone [LC-MS/MS], Norandrostenedione [LC-MS/MS], Norethandrolone Metabolite [LC-MS/MS], Norethandrolone [LC-MS/MS], Norethindrone [LC-MS/MS], Oxandrolone [LC-MS/MS], Oxymetholone Metabolite [LC-MS/MS], Probenecid [LC-MS/MS], Stanozolol Metabolite [LC-MS/MS], Stanozolol [LC-MS/MS], Testosterone [LC-MS/MS], Testosterone/Epitestosterone Ratio [LC-MS/MS], Tetrahydrogestrinone [LC-MS/MS], Trenbolone Metabolite [LC-MS/MS], Turinabol [LC-MS/MS]
Method(s):	Colorimetry (C) High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Exclusion Screen
Category:	Androgen, Biological Marker (Renal), Biological Marker (Exposure)
Specimen Requirements:	9 mL Urine
Minimum Volume:	4.3 mL
Special Handling:	None
Specimen Container:	Plastic container (preservative-free)
Transport Temperature:	Frozen
Light Protection:	Not Required
Rejection Criteria:	None
Stability:	Room Temperature: Undetermined Refrigerated: 7 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday Friday 5 days (after set-up)

CPT Code: 80100

Compound Name / Alias	Units	RL	Reference Comment
Androstenedione 4-androstene-3,17-dione	ng/mL	10	
Bolasterone 4-androsten-7alpha,17alpha-dimethyl-17beta-ol-3-one	ng/mL	10	
Boldenone 1-dehydrotestosterone	ng/mL	10	
Clostebol 4-androsten-4-chloro-17beta-ol-3-one	ng/mL	10	
Clostebol Metabolite 4-chloro-4-androsten-3alpha-ol-17-one	ng/mL	10	
Clenbuterol Planipart®	ng/mL	10	
Drostanolone Metabolite 2alpha-methyl-5alpha-androstan-3alpha-ol-17-one	ng/mL	10	
Norethandrolone 17-hydroxy-19-norpregn-4-en-3-one	ng/mL	10	
Fluoxymesterone 9alpha-fluoro-11beta,17beta-dihydroxy-17alpha-methyl-androst-4-en-3-one	ng/mL	10	
Methandienone 17-hydroxy-17-methylandrosta-1,4-dien-3-one	ng/mL	10	

New Tests and Test Updates

New Tests

Compound Name / Alias	Units	RL	Reference Comment
Methandienone Metabolite 6beta-hydroxymethandienone	ng/mL	10	
Methenolone (5alpha,17beta)-17-hydroxy-1-methylandrost-1-en-3-one	ng/mL	10	
Methyltestosterone 17beta-hydroxy-17alpha-methylandrost-4-en-3-one	ng/mL	10	
Nandrolone 17beta-hydroxy-19-norandrost-4-en-3-one	ng/mL	10	
Nandrolone Metabolite 5alpha-estran-3alpha-ol-17-one; norandrosterone	ng/mL	10	
Norandrostenedione 4-estren-3,17-dione	ng/mL	10	
Norethandrolone Metabolite 17alpha-ethyl-5beta-estrane-3alpha,17beta-diol	ng/mL	10	
Norethindrone Camila®; Ortho-Novum®	ng/mL	10	
Oxandrolone 17beta-hydroxy-17alpha-methyl-2-oxandrostan-3-one	ng/mL	10	
Oxymetholone Metabolite 17alpha-methyl-5alpha-androstane-3alpha,17beta-diol; Mestanolone Metabolite; Methyltestosterone Metabolite	ng/mL	10	
Probenecid Benemid®	ng/mL	10	
Stanozolol 17alpha-methyl-2'H-androst-2-eno[3,2-c]pyrazol-17beta-ol	ng/mL	10	
Stanozolol Metabolite 3'-hydroxystanozolol	ng/mL	10	
Turinabol dehydrochlormethyltestosterone	ng/mL	10	
Tetrahydrogestrinone 18alpha-homo-17-hydroxy-19-nor-17alpha-pregna-4,9,11-trien-3-one; THG	ng/mL	10	
Trenbolone Metabolite 17a-trenbolone	ng/mL	10	
Testosterone 17beta-hydroxyandrost-4-en-3-one	ng/mL	2	
Epitestosterone 4-androsten-17alpha-ol-3-one	ng/mL	2	
Testosterone/Epitestosterone Ratio			A T/E ratio less than 4.0 is considered normal, while a ratio greater than or equal to 4.0 is considered an abnormal finding suggestive of testosterone use/abuse. This cut-off for the T/E ratio is recommended by the World Anti-Doping Agency.

Method: Colorimetry (C)

Set-Up Days / TAT: Thursday 2nd Shift 1 day (after set-up)

CPT Code: 82570

New Tests and Test Updates

New Tests

Compound Name / Alias	Units	RL	Reference Comment
Creatinine	mg/L	5	ACGIH Normal range in adults: 300 - 3400 mg/L (mean: 1000 mg/L) [0.3 - 3.4 g/L (mean: 1 g/L)] 1000 - 1600 mg/day (1.0 - 1.6 g/day).

9022B Antidepressants Screen - Expanded, Blood — Effective Immediately

Scope of Analysis:	Amitriptyline [LC-MS/MS], Amoxapine [LC-MS/MS], Bupropion [LC-MS/MS], Citalopram / Escitalopram [LC-MS/MS], Clomipramine [LC-MS/MS], Desipramine [LC-MS/MS], Desmethylclomipramine [LC-MS/MS], Desmethyldoxepin [LC-MS/MS], Desmethyltrimipramine [LC-MS/MS], Doxepin [LC-MS/MS], Duloxetine [LC-MS/MS], Fluoxetine [LC-MS/MS], Fluvoxamine [LC-MS/MS], Hydroxybupropion [LC-MS/MS], Imipramine [LC-MS/MS], Maprotiline [LC-MS/MS], Mirtazapine [LC-MS/MS], Nefazodone [LC-MS/MS], Norfluoxetine [LC-MS/MS], Nortriptyline [LC-MS/MS], O-Desmethylvenlafaxine [LC-MS/MS], Paroxetine [LC-MS/MS], Protriptyline [LC-MS/MS], Sertraline [LC-MS/MS], Trazodone [LC-MS/MS], Trimipramine [LC-MS/MS], Venlafaxine [LC-MS/MS]
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Forensic Analysis
Category:	Antidepressant
Specimen Requirements:	6 mL Blood
Minimum Volume:	2.8 mL
Special Handling:	Ensure that container remains tightly sealed.
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Stability:	Room Temperature: Undetermined Refrigerated: Undetermined Frozen (-20 °C): Undetermined

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT:	Tuesday 3 days (after set-up)
CPT Code:	80100

Compound Name / Alias	Units	RL	Reference Comment
Paroxetine Paxil®	ng/mL	2	Trough steady-state Plasma levels in adult patients have great inter-individual variability. The following steady-state data is from patients on a daily single dose regimen and represent the mean +/- 1 SD: 49 +/- 26 ng/mL (20 mg/day), 86 +/- 61 ng/mL (30 mg/day), 129 +/- 86 ng/mL (40 mg/day), 117 +/- 90 ng/mL (50 mg/day).
Sertraline Zoloft®	ng/mL	1	Following single oral doses of 50, 100, 200, 300 and 400 mg, the peak plasma levels were 9.5, 16, 56, 78, and 88 ng/mL, respectively, and occurred at 6 to 10 hours post dose. Mean peak steady-state plasma levels following daily regimens of 50, 100, 150 and 200 mg/day were 32, 54, 144 and 190 ng/mL, respectively, and occurred at 4.5 to 8.4 hours following the last dose.
Amoxapine Asendin®	ng/mL	10	Therapeutic concentration following a 300 mg regimen: 17 - 93 ng/mL.
Clomipramine Anafranil®	ng/mL	10	
Desipramine Imipramine Metabolite; Norpramin®; Pertofrane®	ng/mL	10	Desipramine is a metabolite of Imipramine and is also available as an independent therapeutic agent. When Imipramine is the administered drug: Usual therapeutic range for the total of Imipramine plus Desipramine: 150 - 400 ng/mL. When Desipramine is the administered drug: Usual therapeutic range in outpatients on 100 to 200 mg Desipramine/day: 40 - 250 ng/mL.

New Tests and Test Updates

New Tests

Compound Name / Alias	Units	RL	Reference Comment
Desmethylclomipramine Clomipramine Metabolite	ng/mL	10	The plasma concentrations of Clomipramine and metabolite vary widely between patients. The suggested antidepressant range for the sum of Clomipramine plus Desmethylclomipramine: 200 - 500 ng/mL plasma.
Desmethyltrimipramine Trimipramine Metabolite	ng/mL	10	Observed concentrations during chronic antidepressant doses of 75 to 150 mg/day: 3 - 380 ng/mL.
Imipramine Tofranil®	ng/mL	10	
Maprotiline Ludiomil®	ng/mL	10	Following daily oral doses of 50, 100 and 150 mg, the steady-state mean blood concentrations were 70, 140 and 220 ng/mL respectively.
Protriptyline Vivactil®	ng/mL	10	Usual antidepressant range: 70 - 250 ng/mL.
Trimipramine Surmontil®	ng/mL	10	Observed levels during chronic oral antidepressant doses of 75 to 150 mg/day: 10 - 240 ng/mL.
Amitriptyline Elavil®; Endep®	ng/mL	10	
Desmethyldoxepin Doxepin Metabolite	ng/mL	10	Patients on an average antidepressant dose of 113 mg Doxepin/day: 0 - 80 ng Desmethyldoxepin/mL.
Doxepin Sinequan®	ng/mL	10	Patients on an average antidepressant dose of 113 mg Doxepin/day: 5 - 115 ng Doxepin/mL.
Fluoxetine Prozac®	ng/mL	10	Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 91 - 302 ng/mL serum.
Mirtazapine Remeron®	ng/mL	5	Steady-state peak (0.7 to 4.8 hours post-dose) and trough plasma concentrations following a daily regimen: 15 mg/day: 27 - 51 ng/mL peak; 4.3 - 12 ng/mL trough 30 mg/day: 56 - 104 ng/mL peak; 11 - 25 ng/mL trough 45 mg/day: 84 - 142 ng/mL peak; 17 - 39 ng/mL trough 60 mg/day: 117 - 199 ng/mL peak; 24 - 52 ng/mL trough 75 mg/day: 137 - 225 ng/mL peak; 28 - 64 ng/mL trough Elimination half-life: 20 to 40 hours.
Norfluoxetine Fluoxetine Metabolite	ng/mL	10	Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 72 - 258 ng/mL serum.
Nortriptyline Amitriptyline Metabolite; Aventyl®; Pamelor®	ng/mL	10	Nortriptyline is a metabolite of Amitriptyline and is also available as an independent therapeutic agent. When Amitriptyline is the administered drug: Usual therapeutic range for the total of Amitriptyline plus Nortriptyline: 80 - 250 ng/mL. When Nortriptyline is the administered drug: Usual therapeutic range: 50 - 150 ng/mL.
Trazodone Desyrel®	ng/mL	50	Therapeutic range: 0.3 - 1.5 mcg/mL.
Citalopram / Escitalopram Celexa® / Lexapro®	ng/mL	5	Steady-state serum or plasma levels from patients on a daily regimen of 30 to 60 mg Citalopram: 9 - 200 ng/mL. Steady-state peak plasma levels from patients on a regimen of 10 or 30 mg Escitalopram: 21 and 64 ng/mL, respectively, and occur at approximately 4 hours post dose. This test is not chiral specific; therefore, citalopram and/or escitalopram may be present.

New Tests and Test Updates

New Tests

Compound Name / Alias	Units	RL	Reference Comment
Fluvoxamine Luvox®	ng/mL	10	Steady-state plasma levels following a daily regimen of 150 to 300 mg/day: 78 - 920 ng/mL (mean of 510).
Nefazodone Serzone®	ng/mL	25	Steady-state peak plasma levels (at approximately 1.2 hours post dose) following a daily regimen: 50 mg b.i.d.: 0.08 - 0.39 mcg/mL 100 mg b.i.d.: 0.46 - 1.2 mcg/mL 200 mg b.i.d.: 1.6 - 3.9 mcg/mL
Bupropion Wellbutrin®	ng/mL	10	Maximum antidepressant response was observed at trough plasma concentrations of 50 - 100 ng/mL bupropion with virtually no response below 25 ng/mL. Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma levels: 100 mg/day (n = 11), 25 +/- 8 ng/mL bupropion 200 mg/day (n = 8), 53 +/- 22 ng/mL bupropion The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte. Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative values.
Hydroxybupropion Bupropion Metabolite	ng/mL	100	Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma levels: 100 mg/day (n = 11), 450 +/- 210 ng/mL hydroxybupropion 200 mg/day (n = 8), 710 +/- 350 ng/mL hydroxybupropion The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.
Duloxetine Cymbalta®	ng/mL	3	Steady-state trough plasma concentrations after 5 days of oral therapy were: 20 mg twice daily: 4 to 22 ng/mL 30 mg twice daily: 8 to 48 ng/mL 40 mg twice daily: 12 to 60 ng/mL.
O-Desmethylvenlafaxine Desvenlafaxine; Pristiq®; Venlafaxine Metabolite	ng/mL	10	Steady-state peak plasma levels following a daily regimen of Venlafaxine occur at approximately 2.5 hours for O-Desmethylvenlafaxine: 94 - 200 ng/mL (75 mg/day), 85 - 472 ng/mL (150 mg/day), 243 - 515 ng/mL (225 mg/day), 390 - 1096 ng/mL (450 mg/day). Steady-state trough plasma levels following a 150 mg per day regimen: 65 - 300 ng O-Desmethylvenlafaxine/mL.
Venlafaxine Effexor®	ng/mL	10	Steady-state peak plasma levels following a daily regimen occur at 2 hours for Venlafaxine: 35 - 79 ng/mL (75 mg/day), 93 - 334 ng/mL (150 mg/day), 68 - 265 ng/mL (225 mg/day), 196 - 597 ng/mL (450 mg/day). Steady-state trough plasma concentrations following a 150 mg per day regimen: 0 - 141 ng/mL.

New Tests and Test Updates

New Tests

9022SP Antidepressants Screen - Expanded, Serum/Plasma **Effective Immediately**

Scope of Analysis:	Amitriptyline [LC-MS/MS], Amoxapine [LC-MS/MS], Bupropion [LC-MS/MS], Citalopram / Escitalopram [LC-MS/MS], Clomipramine [LC-MS/MS], Desipramine [LC-MS/MS], Desmethylclomipramine [LC-MS/MS], Desmethyldoxepin [LC-MS/MS], Desmethyltrimipramine [LC-MS/MS], Doxepin [LC-MS/MS], Duloxetine [LC-MS/MS], Fluoxetine [LC-MS/MS], Fluvoxamine [LC-MS/MS], Hydroxybupropion [LC-MS/MS], Imipramine [LC-MS/MS], Maprotiline [LC-MS/MS], Mirtazapine [LC-MS/MS], Nefazodone [LC-MS/MS], Norfluoxetine [LC-MS/MS], Nortriptyline [LC-MS/MS], O-Desmethylvenlafaxine [LC-MS/MS], Paroxetine [LC-MS/MS], Protriptyline [LC-MS/MS], Sertraline [LC-MS/MS], Trazodone [LC-MS/MS], Trimipramine [LC-MS/MS], Venlafaxine [LC-MS/MS]
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Forensic Analysis
Category:	Antidepressant
Specimen Requirements:	6 mL Serum or Plasma
Minimum Volume:	2.8 mL
Special Handling:	Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Ensure that container remains tightly sealed.
Specimen Container:	Plastic container (preservative-free)
Transport Temperature:	Refrigerated
Light Protection:	Yes
Rejection Criteria:	Not received Light Protected. Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: Undetermined Refrigerated: Undetermined Frozen (-20 °C): Undetermined

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday 3 days (after set-up)

CPT Code: 80100

Compound Name / Alias	Units	RL	Reference Comment
Paroxetine Paxil®	ng/mL	2	Trough steady-state Plasma levels in adult patients have great inter-individual variability. The following steady-state data is from patients on a daily single dose regimen and represent the mean +/- 1 SD: 49 +/- 26 ng/mL (20 mg/day), 86 +/- 61 ng/mL (30 mg/day), 129 +/- 86 ng/mL (40 mg/day), 117 +/- 90 ng/mL (50 mg/day).
Sertraline Zoloft®	ng/mL	1	Following single oral doses of 50, 100, 200, 300 and 400 mg, the peak plasma levels were 9.5, 16, 56, 78, and 88 ng/mL, respectively, and occurred at 6 to 10 hours post dose. Mean peak steady-state plasma levels following daily regimens of 50, 100, 150 and 200 mg/day were 32, 54, 144 and 190 ng/mL, respectively, and occurred at 4.5 to 8.4 hours following the last dose.
Amoxapine Asendin®	ng/mL	10	Therapeutic concentration following a 300 mg regimen: 17 - 93 ng/mL.
Clomipramine Anafranil®	ng/mL	10	
Desipramine Imipramine Metabolite; Norpramin®; Pertofrane®	ng/mL	10	Desipramine is a metabolite of Imipramine and is also available as an independent therapeutic agent. When Imipramine is the administered drug: Usual therapeutic range for the total of Imipramine plus Desipramine: 150 - 400 ng/mL. When Desipramine is the administered drug: Usual therapeutic range in outpatients on 100 to 200 mg Desipramine/day: 40 - 250 ng/mL.

New Tests and Test Updates

New Tests

Compound Name / Alias	Units	RL	Reference Comment
Desmethylclomipramine Clomipramine Metabolite	ng/mL	10	The plasma concentrations of Clomipramine and metabolite vary widely between patients. The suggested antidepressant range for the sum of Clomipramine plus Desmethylclomipramine: 200 - 500 ng/mL plasma.
Desmethyltrimipramine Trimipramine Metabolite	ng/mL	10	Observed concentrations during chronic antidepressant doses of 75 to 150 mg/day: 3 - 380 ng/mL.
Imipramine Tofranil®	ng/mL	10	
Maprotiline Ludiomil®	ng/mL	10	Following daily oral doses of 50, 100 and 150 mg, the steady-state mean blood concentrations were 70, 140 and 220 ng/mL respectively.
Protriptyline Vivactil®	ng/mL	10	Usual antidepressant range: 70 - 250 ng/mL.
Trimipramine Surmontil®	ng/mL	10	Observed levels during chronic oral antidepressant doses of 75 to 150 mg/day: 10 - 240 ng/mL.
Amitriptyline Elavil®; Endep®	ng/mL	10	
Desmethyldoxepin Doxepin Metabolite	ng/mL	10	Patients on an average antidepressant dose of 113 mg Doxepin/day: 0 - 80 ng Desmethyldoxepin/mL.
Doxepin Sinequan®	ng/mL	10	Patients on an average antidepressant dose of 113 mg Doxepin/day: 5 - 115 ng Doxepin/mL.
Fluoxetine Prozac®	ng/mL	10	Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 91 - 302 ng/mL serum.
Mirtazapine Remeron®	ng/mL	5	Steady-state peak (0.7 to 4.8 hours post-dose) and trough plasma concentrations following a daily regimen: 15 mg/day: 27 - 51 ng/mL peak; 4.3 - 12 ng/mL trough 30 mg/day: 56 - 104 ng/mL peak; 11 - 25 ng/mL trough 45 mg/day: 84 - 142 ng/mL peak; 17 - 39 ng/mL trough 60 mg/day: 117 - 199 ng/mL peak; 24 - 52 ng/mL trough 75 mg/day: 137 - 225 ng/mL peak; 28 - 64 ng/mL trough Elimination half-life: 20 to 40 hours.
Norfluoxetine Fluoxetine Metabolite	ng/mL	10	Daily therapy with 40 mg Fluoxetine/day: Steady-state concentration at 4 to 8 hours after dosing ranges from 72 - 258 ng/mL serum.
Nortriptyline Amitriptyline Metabolite; Aventyl®; Pamelor®	ng/mL	10	Nortriptyline is a metabolite of Amitriptyline and is also available as an independent therapeutic agent. When Amitriptyline is the administered drug: Usual therapeutic range for the total of Amitriptyline plus Nortriptyline: 80 - 250 ng/mL. When Nortriptyline is the administered drug: Usual therapeutic range: 50 - 150 ng/mL.
Trazodone Desyrel®	ng/mL	50	Therapeutic range: 0.3 - 1.5 mcg/mL.
Citalopram / Escitalopram Celexa® / Lexapro®	ng/mL	5	Steady-state serum or plasma levels from patients on a daily regimen of 30 to 60 mg Citalopram: 9 - 200 ng/mL. Steady-state peak plasma levels from patients on a regimen of 10 or 30 mg Escitalopram: 21 and 64 ng/mL, respectively, and occur at approximately 4 hours post dose. This test is not chiral specific; therefore, citalopram and/or escitalopram may be present.

New Tests and Test Updates

New Tests

Compound Name / Alias	Units	RL	Reference Comment
Fluvoxamine Luvox®	ng/mL	10	Steady-state plasma levels following a daily regimen of 150 to 300 mg/day: 78 - 920 ng/mL (mean of 510).
Nefazodone Serzone®	ng/mL	25	Steady-state peak plasma levels (at approximately 1.2 hours post dose) following a daily regimen: 50 mg b.i.d.: 0.08 - 0.39 mcg/mL 100 mg b.i.d.: 0.46 - 1.2 mcg/mL 200 mg b.i.d.: 1.6 - 3.9 mcg/mL
Bupropion Wellbutrin®	ng/mL	10	Maximum antidepressant response was observed at trough plasma concentrations of 50 - 100 ng/mL bupropion with virtually no response below 25 ng/mL. Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma levels: 100 mg/day (n = 11), 25 +/- 8 ng/mL bupropion 200 mg/day (n = 8), 53 +/- 22 ng/mL bupropion Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative values.
Hydroxybupropion Bupropion Metabolite	ng/mL	100	Juvenile patients taking once daily, extended release bupropion for two weeks had the following peak plasma levels: 100 mg/day (n = 11), 450 +/- 210 ng/mL hydroxybupropion 200 mg/day (n = 8), 710 +/- 350 ng/mL hydroxybupropion
Duloxetine Cymbalta®	ng/mL	3	Steady-state trough plasma concentrations after 5 days of oral therapy were: 20 mg twice daily: 4 to 22 ng/mL 30 mg twice daily: 8 to 48 ng/mL 40 mg twice daily: 12 to 60 ng/mL.
O-Desmethylvenlafaxine Desvenlafaxine; Pristiq®; Venlafaxine Metabolite	ng/mL	10	Steady-state peak plasma levels following a daily regimen of Venlafaxine occur at approximately 2.5 hours for O-Desmethylvenlafaxine: 94 - 200 ng/mL (75 mg/day), 85 - 472 ng/mL (150 mg/day), 243 - 515 ng/mL (225 mg/day), 390 - 1096 ng/mL (450 mg/day). Steady-state trough plasma levels following a 150 mg per day regimen: 65 - 300 ng O-Desmethylvenlafaxine/mL.
Venlafaxine Effexor®	ng/mL	10	Steady-state peak plasma levels following a daily regimen occur at 2 hours for Venlafaxine: 35 - 79 ng/mL (75 mg/day), 93 - 334 ng/mL (150 mg/day), 68 - 265 ng/mL (225 mg/day), 196 - 597 ng/mL (450 mg/day). Steady-state trough plasma concentrations following a 150 mg per day regimen: 0 - 141 ng/mL.

9022U Antidepressants Screen - Expanded, Urine **Effective Immediately**

Scope of Analysis: Amitriptyline [LC-MS/MS], Amoxapine [LC-MS/MS], Bupropion [LC-MS/MS], Citalopram / Escitalopram [LC-MS/MS], Clomipramine [LC-MS/MS], Desipramine [LC-MS/MS], Desmethylclomipramine [LC-MS/MS], Desmethyldoxepin [LC-MS/MS], Desmethyltrimipramine [LC-MS/MS], Doxepin [LC-MS/MS], Fluoxetine [LC-MS/MS], Fluvoxamine [LC-MS/MS], Hydroxybupropion [LC-MS/MS], Imipramine [LC-MS/MS], Maprotiline [LC-MS/MS], Mirtazapine [LC-MS/MS], Nefazodone [LC-MS/MS], Norfluoxetine [LC-MS/MS], Nortriptyline [LC-MS/MS], O-Desmethylvenlafaxine [LC-MS/MS], Paroxetine [LC-MS/MS], Protriptyline [LC-MS/MS], Sertraline [LC-MS/MS], Trazodone [LC-MS/MS], Trimipramine [LC-MS/MS], Venlafaxine [LC-MS/MS]

Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

New Tests and Test Updates

New Tests

Purpose: Forensic Analysis
Category: Antidepressant
Specimen Requirements: 6 mL Urine
Minimum Volume: 2.8 mL
Special Handling: None
Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Stability: Room Temperature: Undetermined
Refrigerated: Undetermined
Frozen (-20 °C): Undetermined

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday 3 days (after set-up)
CPT Code: 80100

Compound Name / Alias	Units	RL	Reference Comment
Paroxetine Paxil®	ng/mL	2	No reference data available.
Sertraline Zoloft®	ng/mL	1	No reference data available.
Amoxapine Asendin®	ng/mL	10	
Clomipramine Anafranil®	ng/mL	10	
Desipramine Imipramine Metabolite; Norpramin®; Pertofrane®	ng/mL	10	Desipramine is a metabolite of Imipramine and is also available as an independent therapeutic agent. 24-hour post-dose urine typically contains less than 1% of an administered dose.
Desmethylclomipramine Clomipramine Metabolite	ng/mL	10	
Desmethyltrimipramine Trimipramine Metabolite	ng/mL	10	
Imipramine Tofranil®	ng/mL	10	
Maprotiline Ludiomil®	ng/mL	10	
Protriptyline Vivactil®	ng/mL	10	
Trimipramine Surmontil®	ng/mL	10	
Amitriptyline Elavil®; Endep®	ng/mL	10	
Desmethyldoxepin Doxepin Metabolite	ng/mL	10	
Doxepin Sinequan®	ng/mL	10	
Fluoxetine Prozac®	ng/mL	10	
Mirtazapine Remeron®	ng/mL	5	

New Tests and Test Updates

New Tests

Compound Name / Alias	Units	RL	Reference Comment
Norfluoxetine Fluoxetine Metabolite	ng/mL	10	
Nortriptyline Amitriptyline Metabolite; Aventyl®; Pamelor®	ng/mL	10	Nortriptyline is a metabolite of Amitriptyline and is also available as an independent therapeutic agent. Less than 5% of a given dose is typically excreted as unchanged drug in 24-hour post-dose urine.
Trazodone Desyrel®	ng/mL	50	
Citalopram / Escitalopram Celexa® / Lexapro®	ng/mL	5	At steady-state, approximately 23% of an oral dose is excreted into the urine as unchanged drug.
Fluvoxamine Luvox®	ng/mL	10	No reference data available.
Nefazodone Serzone®	ng/mL	25	No reference data available.
Bupropion Wellbutrin®	ng/mL	10	Less than 0.5% of an oral dose is excreted unchanged in urine. Specimens must be kept frozen. If specimens are not kept frozen, this may cause lower or negative result values.
Hydroxybupropion Bupropion Metabolite	ng/mL	100	Urinary elimination of hydroxybupropion accounts for approximately 4% of a bupropion dose
O-Desmethylvenlafaxine Desvenlafaxine; Pristiq®; Venlafaxine Metabolite	ng/mL	10	
Venlafaxine Effexor®	ng/mL	10	

4280U Synthetic Cannabinoid Metabolites (Qualitative), Urine — Effective Immediately

Scope of Analysis:	JWH-018 Hydroxy-metabolites [LC-MS/MS], JWH-073 Hydroxy-metabolites [LC-MS/MS]
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Exposure Monitoring/Abuse Monitoring
Category:	Synthetic Cannabinoid
Specimen Requirements:	2 mL Urine
Minimum Volume:	1.2 mL
Special Handling:	None
Specimen Container:	Plastic container (preservative-free)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT:	Tuesday Thursday 3 days (after set-up)
CPT Code:	83788

Compound Name / Alias	Units	RL	Reference Comment
JWH-018 Hydroxy-metabolites K2; Space; Spice; Spike; Synthetic Cannabinoids; Yucatan Fire			JWH-018, a synthetic cannabinoid, has been identified in products sold as 'herbal incense'. These products are sold under a wide variety of names including (but not limited to) Spice, Yucatan Fire, Smoke, Sence, K2, Skunk, Space, K2 Citron, and K2 Blonde. These products may be used as an alternative to marijuana. This analysis detects both mono- and di-hydroxy metabolites of JWH-018 using multiple LC-MS/MS transitions for both metabolites. A positive finding indicates that both hydroxyl metabolites were detected and is consistent with exposure to JWH-018.

New Tests and Test Updates

New Tests

Compound Name / Alias	Units	RL	Reference Comment
JWH-073 Hydroxy-metabolites K2; Space; Spice; Spike; Synthetic Cannabinoids; Yucatan Fire			JWH-073, a synthetic cannabinoid, has been identified in products sold as 'herbal incense'. These products are sold under a wide variety of names including (but not limited to) Spice, Yucatan Fire, Smoke, Sence, K2, Skunk, Space, K2 Citron, and K2 Blonde. These products may be used as an alternative to marijuana. This analysis detects both mono- and di-hydroxy metabolites of JWH-073 using multiple LC-MS/MS transitions for both metabolites. A positive finding indicates that both hydroxyl metabolites were detected and is consistent with exposure to JWH-073.

9561U **Synthetic Cannabinoid Metabolites Screen (Qualitative), Urine (Forensic)** **Effective Immediately**

Scope of Analysis:	JWH-018 Hydroxy-metabolites [LC-MS/MS], JWH-073 Hydroxy-metabolites [LC-MS/MS]
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Forensic Analysis
Category:	Synthetic Cannabinoid
Specimen Requirements:	3 mL Urine
Minimum Volume:	2.4 mL
Special Handling:	None
Specimen Container:	Plastic container (preservative-free)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT:	Tuesday Thursday 3 days (after set-up)
CPT Code:	80100

Compound Name / Alias	Units	RL	Reference Comment
JWH-018 Hydroxy-metabolites K2; Space; Spice; Spike; Synthetic Cannabinoids; Yucatan Fire			JWH-018, a synthetic cannabinoid, has been identified in products sold as 'herbal incense'. These products are sold under a wide variety of names including (but not limited to) Spice, Yucatan Fire, Smoke, Sence, K2, Skunk, Space, K2 Citron, and K2 Blonde. These products may be used as an alternative to marijuana.
JWH-073 Hydroxy-metabolites K2; Space; Spice; Spike; Synthetic Cannabinoids; Yucatan Fire			JWH-073, a synthetic cannabinoid, has been identified in products sold as 'herbal incense'. These products are sold under a wide variety of names including (but not limited to) Spice, Yucatan Fire, Smoke, Sence, K2, Skunk, Space, K2 Citron, and K2 Blonde. These products may be used as an alternative to marijuana.

New Tests and Test Updates

New Tests

9561B Synthetic Cannabinoids Screen (Qualitative), Blood (Forensic) — **Effective Immediately**

Scope of Analysis:	JWH-018 [LC-MS/MS], JWH-019 [LC-MS/MS], JWH-073 [LC-MS/MS], JWH-250 [LC-MS/MS]
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Forensic Analysis; Exposure Monitoring/Abuse Monitoring
Category:	Synthetic Cannabinoid
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.8 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT:	Tuesday 3 days (after set-up)
CPT Code:	80100

Compound Name / Alias	Units	RL	Reference Comment
JWH-018 K2; Space; Spice; Spike; Synthetic Cannabinoids; Yucatan Fire	ng/mL	0.1	JWH-018, a synthetic cannabinoid, has been identified in products sold as 'herbal incense'. These products are sold under a wide variety of names including (but not limited to) Spice, Yucatan Fire, Smoke, Sence, K2, Skunk, Space, K2 Citron, and K2 Blonde. These products may be used as an alternative to cannabis. Initial reports indicate that JWH-018 undergoes hydroxylation and glucuronidation and these metabolites are eliminated in urine.
JWH-019 K2; Space; Spice; Spike; Synthetic Cannabinoids; Yucatan Fire	ng/mL	0.1	JWH-019 is a synthetic cannabinoid that may be used as an alternative to cannabis. No information is available on the metabolism of JWH-019.
JWH-073 K2; Space; Spice; Spike; Synthetic Cannabinoids; Yucatan Fire	ng/mL	0.1	JWH-073, a synthetic cannabinoid, has been identified in products sold as 'herbal incense'. These products are sold under a wide variety of names including (but not limited to) Spice, Yucatan Fire, Smoke, Sence, K2, Skunk, Space, K2 Citron, and K2 Blonde. These products may be used as an alternative to cannabis. Initial reports indicate that JWH-073 undergoes hydroxylation and glucuronidation and these metabolites are eliminated in urine.
JWH-250 K2; Space; Spice; Spike; Synthetic Cannabinoids; Yucatan Fire	ng/mL	0.1	JWH-250, a synthetic cannabinoid, has been identified in products sold as 'herbal incense'. These products are sold under a wide variety of names including (but not limited to) Spice, Yucatan Fire, Smoke, Sence, K2, Skunk, Space, K2 Citron, and K2 Blonde. These products may be used as an alternative to cannabis. No information is available on the metabolism of JWH-250

New Tests and Test Updates

New Tests

9560B Synthetic Cannabinoids Screen, Blood (Forensic) Effective Immediately

Scope of Analysis:	JWH-018 [LC-MS/MS], JWH-073 [LC-MS/MS], JWH-250 [LC-MS/MS]
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Forensic Analysis; Exposure Monitoring/Abuse Monitoring
Category:	Synthetic Cannabinoid
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.8 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT:	Tuesday 3 days (after set-up)
CPT Code:	80100

Compound Name / Alias	Units	RL	Reference Comment
JWH-018 K2; Space; Spice; Spike; Synthetic Cannabinoids; Yucatan Fire	ng/mL	0.1	JWH-018, a synthetic cannabinoid, has been identified in products sold as 'herbal incense'. These products are sold under a wide variety of names including (but not limited to) Spice, Yucatan Fire, Smoke, Sence, K2, Skunk, Space, K2 Citron, and K2 Blonde. These products may be used as an alternative to cannabis. Initial reports indicate that JWH-018 undergoes hydroxylation and glucuronidation and these metabolites are eliminated in urine. Two volunteers smoked cigarettes containing 100 mg or 150 mg of an herbal incense containing an unknown amount of JWH-018. Peak serum concentrations were of 8.1 and 10.2 ng/mL, respectively, 5 minutes post-dose. Serum concentrations in both volunteers were <0.5 ng/mL 3 hours post dose.
JWH-073 K2; Space; Spice; Spike; Synthetic Cannabinoids; Yucatan Fire	ng/mL	0.1	JWH-073, a synthetic cannabinoid, has been identified in products sold as 'herbal incense'. These products are sold under a wide variety of names including (but not limited to) Spice, Yucatan Fire, Smoke, Sence, K2, Skunk, Space, K2 Citron, and K2 Blonde. These products may be used as an alternative to cannabis. Initial reports indicate that JWH-073 undergoes hydroxylation and glucuronidation and these metabolites are eliminated in urine.
JWH-250 K2; Space; Spice; Spike; Synthetic Cannabinoids; Yucatan Fire	ng/mL	0.1	JWH-250, a synthetic cannabinoid, has been identified in products sold as 'herbal incense'. These products are sold under a wide variety of names including (but not limited to) Spice, Yucatan Fire, Smoke, Sence, K2, Skunk, Space, K2 Citron, and K2 Blonde. These products may be used as an alternative to cannabis. No information is available on the metabolism of JWH-250

New Tests and Test Updates

Test Changes

0021TI Acetaldehyde, Tissue

Summary of Changes: Units were changed.

Scope of Analysis: Method (CPT Code): GC (80103, 82000): Acetaldehyde

0155B Actifed®, Blood

Summary of Changes: Test Name was changed.

0155SP Actifed®, Serum/Plasma

Summary of Changes: Test Name was changed.

5638SP Antihistamines Confirmation, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): GC/MS (80102): Pheniramine, Diphenhydramine, Orphenadrine, Doxylamine, Chlorpheniramine, Tripelennamine, Methapyrilene, Carbinoxamine, Brompheniramine, Bromodiphenhydramine, Chlorcyclizine, Pyrilamine, Promethazine, Triprolidine, Azatadine

5638U Antihistamines Confirmation, Urine

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): GC/MS (80102): Pheniramine, Diphenhydramine, Orphenadrine, Doxylamine, Chlorpheniramine, Tripelennamine, Methapyrilene, Carbinoxamine, Brompheniramine, Bromodiphenhydramine, Chlorcyclizine, Pyrilamine, Promethazine, Triprolidine, Azatadine

0408B Antihistamines Panel, Blood

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): GC (82492): Pheniramine, Diphenhydramine, Orphenadrine, Doxylamine, Chlorpheniramine, Tripelennamine, Methapyrilene, Carbinoxamine, Brompheniramine, Bromodiphenhydramine, Chlorcyclizine, Pyrilamine, Promethazine, Triprolidine, Azatadine

0408SP Antihistamines Panel, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): GC (82492): Pheniramine, Diphenhydramine, Orphenadrine, Doxylamine, Chlorpheniramine, Tripelennamine, Methapyrilene, Carbinoxamine, Brompheniramine, Bromodiphenhydramine, Chlorcyclizine, Pyrilamine, Promethazine, Triprolidine, Azatadine

New Tests and Test Updates

Test Changes

0408U Antihistamines Panel, Urine

Summary of Changes:	Reference Comment was changed.
Scope of Analysis: Method (CPT Code)	GC (82492): Pheniramine, Diphenhydramine, Orphenadrine, Doxylamine, Chlorpheniramine, Tripelennamine, Methapyrilene, Carbinoxamine, Brompheniramine, Bromodiphenhydramine, Chlorcyclizine, Pyrilamine, Promethazine, Triprolidine, Azatadine

9108SP Antihistamines Screen, Serum/Plasma

Summary of Changes:	Reference Comment was changed.
Scope of Analysis: Method (CPT Code)	GC (82492): Pheniramine, Diphenhydramine, Orphenadrine, Doxylamine, Chlorpheniramine, Tripelennamine, Methapyrilene, Carbinoxamine, Brompheniramine, Bromodiphenhydramine, Chlorcyclizine, Pyrilamine, Promethazine, Triprolidine, Azatadine

9108U Antihistamines Screen, Urine

Summary of Changes:	Reference Comment was changed.
Scope of Analysis: Method (CPT Code)	GC (82492): Pheniramine, Diphenhydramine, Orphenadrine, Doxylamine, Chlorpheniramine, Tripelennamine, Methapyrilene, Carbinoxamine, Brompheniramine, Bromodiphenhydramine, Chlorcyclizine, Pyrilamine, Promethazine, Triprolidine, Azatadine

6100LI Dialysis Water Analysis

Summary of Changes:	Specimen Requirements (Special Handling) were changed.
Specimen Requirements:	25 mL Liquid
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (Acid washed or Trace metal-free)
Light Protection:	Yes
Special Handling:	Submit in Amber vial or wrap with brown paper. Avoid the use of foil. Avoid seafood consumption for 48 hours prior to sample collection.
Rejection Criteria:	Not received Light Protected.

5503B Dimethyltryptamine Confirmation, Blood

Summary of Changes:	Reference Comment was changed.
Scope of Analysis: Method (CPT Code)	GC/MS (80102): Dimethyltryptamine

5503SP Dimethyltryptamine Confirmation, Serum/Plasma

New Tests and Test Updates

Test Changes

Summary of Changes: Reference Comment was changed.

Scope of Analysis: GC/MS (80102): Dimethyltryptamine
Method (CPT Code)

5503U Dimethyltryptamine Confirmation, Urine

Summary of Changes: Reference Comment was changed.

Scope of Analysis: GC/MS (80102): Dimethyltryptamine
Method (CPT Code)

9156B Dimethyltryptamine Screen, Blood

Summary of Changes: Reference Comment was changed.

Scope of Analysis: GC (82491): Dimethyltryptamine
Method (CPT Code)

9156SP Dimethyltryptamine Screen, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: GC (82491): Dimethyltryptamine
Method (CPT Code)

9156U Dimethyltryptamine Screen, Urine

Summary of Changes: Reference Comment was changed.

Scope of Analysis: GC (82491): Dimethyltryptamine
Method (CPT Code)

1693B Dimethyltryptamine, Blood

Summary of Changes: Reference Comment was changed.

Scope of Analysis: GC (82491): Dimethyltryptamine
Method (CPT Code)

1693SP Dimethyltryptamine, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: GC (82491): Dimethyltryptamine
Method (CPT Code)

1693U Dimethyltryptamine, Urine

New Tests and Test Updates

Test Changes

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): GC (82491): Dimethyltryptamine

1912SP Embeda®, Serum/Plasma

Summary of Changes: Test Name was changed.

1912U Embeda®, Urine

Summary of Changes: Test Name was changed.

1955U Esgic®, Urine

Summary of Changes: Test Name was changed.

2087B Fiorinal®, Blood

Summary of Changes: Test Name was changed.

2087SP Fiorinal®, Serum/Plasma

Summary of Changes: Test Name was changed.

2087U Fiorinal®, Urine

Summary of Changes: Test Name was changed.

2321TI Hydrocarbon and Oxygenated Volatiles Panel, Tissue

Summary of Changes: Units were changed.

Scope of Analysis: Method (CPT Code): GC (80103, 84600): Benzene, Ethyl Benzene, Styrene, Toluene, Xylenes (o,m,p), n-Heptane, n-Hexane, Methylpentanes (2- and 3- Isomers), Pentane, n-Butanol, Ethanol, Isopropanol, n-Propanol, Methanol, Acetaldehyde, Acetone, Methyl Ethyl Ketone, Methyl Isobutyl Ketone, Methyl n-Butyl Ketone, Ethyl Acetate, Diethyl Ether, Methyl Acrylate, Methyl Tertiary Butyl Ether

2365FL Hydroxyzine, Fluid

Summary of Changes: Units were changed.

Scope of Analysis: Method (CPT Code): GC (82491): Hydroxyzine

New Tests and Test Updates

Test Changes

2365U Hydroxyzine, Urine

Summary of Changes:	Units were changed.
Scope of Analysis: Method (CPT Code)	GC (82491): Hydroxyzine

2411TI Inhalants Panel, Solvents, Tissue

Summary of Changes:	Units were changed.
Scope of Analysis: Method (CPT Code)	GC (80103, 84600): Acetone, n-Butyl Alcohol, Amyl Alcohol, Iso-Butyl Alcohol, Iso-Amyl Alcohol, Benzene, Ethanol, Ethyl Acetate, Ethyl Ether, Heptane, Hexane, Isopropanol, Methanol, Methyl Ethyl Ketone, Pentane, Styrene, Toluene, o-Xylene, m-Xylene, p-Xylene

5620FL Pheniramine Confirmation, Fluid

Summary of Changes:	Reference Comment was changed.
Scope of Analysis: Method (CPT Code)	GC/MS (82542): Pheniramine

9231FL Pheniramine Screen, Fluid

Summary of Changes:	Reference Comment was changed.
Scope of Analysis: Method (CPT Code)	GC (80100): Pheniramine

3560B Pheniramine, Blood

Summary of Changes:	Reference Comment was changed.
Scope of Analysis: Method (CPT Code)	GC (82491): Pheniramine

9551B Sildenafil and Metabolite Screen (Add-On), Blood (CSA)

Summary of Changes:	Specimen Requirements were changed.

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None

New Tests and Test Updates

Test Changes

4197B Sildenafil and Metabolite, Blood

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None

4127B Suboxone® - Free, Blood

Summary of Changes: Test Name was changed.

4127SP Suboxone® - Free, Serum/Plasma

Summary of Changes: Test Name was changed.

4127U Suboxone® - Total, Urine

Summary of Changes: Test Name was changed.

3230B Symbyax®, Blood

Summary of Changes: Test Name was changed.

3230FL Symbyax®, Fluid

Summary of Changes: Test Name was changed.

3230SP Symbyax®, Serum/Plasma

Summary of Changes: Test Name was changed.

3230TI Symbyax®, Tissue

Summary of Changes: Test Name was changed.

3230U Symbyax®, Urine

Summary of Changes: Test Name was changed.

New Tests and Test Updates

Test Changes

4541SP **Triavil®, Serum/Plasma**

Summary of Changes: Test Name was changed.

NMS LABS
3701 Welsh Road
Willow Grove, PA 19090
www.NMSLabs.com

New Tests and Test Updates

Discontinued Tests

Test Code	Test Name	Alternative Test
9530U	Antidepressant Screen, Urine (CSA)	No Alternate Tests Available